Breaking News

MannKind Ends Afrezza License with Sanofi

January 5, 2016

Will transition development and commercialization to MannKind

MannKind Corp. has terminated its license and collaboration agreement with Sanofi-aventis U.S. for the development and commercialization of Afrezza (insulin human) Inhalation Powder. The companies will transition the development and commercialization of Afrezza from Sanofi to MannKind within 180 days.
 
MannKind is reviewing its strategic options for Afrezza as a result of the termination of the Sanofi collaboration.
blog comments powered by Disqus